Cover Image
市場調查報告書

慢性蕁麻疹:開發中產品分析

Chronic Urticaria Or Hives - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213077
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
慢性蕁麻疹:開發中產品分析 Chronic Urticaria Or Hives - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 65 Pages
簡介

慢性蕁麻疹指的是身上時而出現時而消失的隆起,有各種大小,呈紅色或白色並發癢的腫疹。大部分情況下,蕁麻疹皆可在1週內穩定,偶而也有人會長期持續這些症狀。持續6週以上的蕁麻疹,及暫時消失但卻又頻繁複發的蕁麻疹就稱為慢性蕁麻疹。

本報告提供全球各國慢性蕁麻疹治療用之開發中產品開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

慢性蕁麻疹概要

治療藥的開發

  • 開發中產品的概要

慢性蕁麻疹:企業開發中的治療藥

慢性蕁麻疹:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

慢性蕁麻疹:企業開發中的產品

慢性蕁麻疹的治療藥開發企業

  • AstraZeneca Plc
  • Biofrontera AG
  • ELORAC, Inc.
  • Faes Farma, SA
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • J Uriach Y Compania, S.A.
  • Mabtech Limited
  • Merck & Co., Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Panacea Biotec Limited

慢性蕁麻疹:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

慢性蕁麻疹:最近的開發平台趨勢

慢性蕁麻疹:暫停中的計劃

慢性蕁麻疹:開發中止的產品

慢性蕁麻疹:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8570IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2016, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 4, 2 and 3 respectively for Chronic Urticaria Or Hives.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Urticaria Or Hives Overview
  • Therapeutics Development
    • Pipeline Products for Chronic Urticaria Or Hives - Overview
  • Chronic Urticaria Or Hives - Therapeutics under Development by Companies
  • Chronic Urticaria Or Hives - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Chronic Urticaria Or Hives - Products under Development by Companies
  • Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
    • Biofrontera AG
    • ELORAC, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Genentech, Inc.
    • GlaxoSmithKline Plc
    • Mabtech Limited
    • Mycenax Biotech Inc.
    • Novartis AG
    • Panacea Biotec Limited
    • Synermore Biologics Co Ltd
  • Chronic Urticaria Or Hives - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BF-Derm-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cidoxepin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2646264 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JDP-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ligelizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • quilizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chronic Urticaria Or Hives - Dormant Projects
  • Chronic Urticaria Or Hives - Discontinued Products
  • Chronic Urticaria Or Hives - Product Development Milestones
    • Featured News & Press Releases
      • Jun 12, 2015: Novartis reports new analysis showing Xolair improving quality of life by 78% for chronic spontaneous urticaria patients
      • Aug 28, 2014: Novartis announces that Xolair is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines
      • May 07, 2014: FDA Approves Xolair for Treatment of Chronic Hives
      • Mar 21, 2014: Novartis announces US FDA approval of Xolair for chronic idiopathic urticaria
      • Mar 06, 2014: Novartis announces Xolair approved in EU as first and only licensed therapy for chronic spontaneous urticaria patients unresponsive to antihistamines
      • Jan 24, 2014: Novartis reports positive opinion from CHMP for Xolair in severe form of skin disease CSU, a debilitating form of hives and chronic itch
      • Oct 11, 2013: FDA Files Genentech's Supplemental Biologics License Application of Xolair for Chronic Idiopathic Urticaria
      • Sep 30, 2013: Novartis to reveal landmark Phase III results of omalizumab at upcoming EADV 2013 congress
      • Jun 26, 2013: Novartis Reports New Phase III Data Showing Omalizumab Significantly Improves Itch In Patients With Severe Form Of CSU
      • Mar 20, 2013: Omalizumab Shows Promise In Eliminating Symptoms Of Chronic Urticaria, Study Finds
      • Feb 24, 2013: Genentech Reports Omalizumab Meets Primary Endpoint In Phase III Results In Patients With Chronic Form Of Hives Who Failed Standard Therapy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Urticaria Or Hives, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Chronic Urticaria Or Hives - Pipeline by Biofrontera AG, H2 2016
  • Chronic Urticaria Or Hives - Pipeline by ELORAC, Inc., H2 2016
  • Chronic Urticaria Or Hives - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Chronic Urticaria Or Hives - Pipeline by Genentech, Inc., H2 2016
  • Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Chronic Urticaria Or Hives - Pipeline by Mabtech Limited, H2 2016
  • Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc., H2 2016
  • Chronic Urticaria Or Hives - Pipeline by Novartis AG, H2 2016
  • Chronic Urticaria Or Hives - Pipeline by Panacea Biotec Limited, H2 2016
  • Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chronic Urticaria Or Hives - Dormant Projects, H2 2016
  • Chronic Urticaria Or Hives - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Chronic Urticaria Or Hives, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top